Peter Hovland is an Ophthalmology physician. OpenAlex indexes 34 publications with 1,632 citations (h-index 13).
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
850 E Harvard Ave
Suite 155
Denver, CO 802105073
Telephone
303-778-1910Registry record last updated 24 Oct 2007.
Industry payments
15 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Genentech, Inc.Program year20251 payment
- Regeneron Healthcare Solutions, Inc.Program year20257 payments
- Astellas Pharma US IncProgram year20254 payments
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Sensory organs
69.4%Antineovascularisation agents68.6%Faricimab-svoa100%Part B, office-administered≥56 patientsCarbonic Anhydrase Inhibitor0.5%Dorzolamide-Timolol67%Dorzolamide Hcl22%Acetazolamide11%Part D<11 patients+ 3 more classes in this area
Cancer & immunology
30.4%Complement Inhibitor25.4%Pegcetacoplan100%Part B, office-administered≥50 patientsVascular Endothelial Growth Factor Inhibitor5%Aflibercept100%Part B, office-administered≥112 patientsCardiovascular
0.1%Beta blocker0.1%Timolol Maleate100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Ultrasmall Gauge Biopsy of Small Choroidal Melanomas with a Subretinal Cannula
Retinal Cases & Brief Reports
2026 - Uveal Melanoma Patient Attitudes Towards Prognostic Testing Using Gene Expression Profiling
Melanoma Management
2022
Similar KOLs
Other experts from the same institution or the same specialty.
No other directory profiles share this institution yet.
Emily Chew, MD
National Eye Institute
Robert Weinreb, MD
University of California San Diego
Harry Quigley, MD
Johns Hopkins University School of Medicine
Joel Schuman, MD
Wills Eye Hospital
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments, shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”